Sarepta Therapeutics, INC Form 4 insider transactions

Bilal Arif, Chief Tech Ops Officer of Sarepta Therapeutics, reports disposing of shares to cover tax withholding obligations related to vesting of restricted stock units.

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports disposing of shares to cover tax withholding obligations related to vesting restricted stock units.

Kathryn Jean Boor, a director at Sarepta Therapeutics, sold 761 shares of common stock on March 11, 2024, to cover tax obligations arising from the vesting of restricted stock units.

EVP and General Counsel of Sarepta Therapeutics, Ryan Edward Brown, reports the sale of company stock to cover tax withholding obligations related to vesting restricted stock units.

Chief Financial Officer of Sarepta Therapeutics, Ian Michael Estepan, reports the disposal of common stock to cover tax withholding obligations related to vesting restricted stock units.

Ian Michael Estepan, CFO of Sarepta Therapeutics, sold 1,389 shares of common stock on March 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Director Stephen Mayo sold 3,135 shares of Sarepta Therapeutics common stock on March 5, 2024, to cover tax obligations arising from the vesting of restricted stock units.

EVP and General Counsel of Sarepta Therapeutics, Ryan Edward Brown, reports the sale of 1,734 shares of common stock to cover tax obligations related to vesting of restricted stock units.

Bilal Arif, Chief Tech Ops Officer of Sarepta Therapeutics, reports the disposal of common stock to cover tax withholding obligations related to vesting restricted stock units.

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Director Claude Nicaise reports acquisition of restricted stock units and stock options in Sarepta Therapeutics.

Director Stephen Mayo reports acquisition of restricted stock units and stock options in Sarepta Therapeutics.

Director Hans Wigzell reports acquisition of restricted stock units and exercise of stock options in Sarepta Therapeutics.

Bilal Arif, Chief Tech Ops Officer at Sarepta Therapeutics, reports acquisition and disposal of company stock and stock options related to vesting of restricted stock units and tax obligations.

Director Michael Chambers reports acquisition of Sarepta Therapeutics stock and stock options, along with disposition of existing shares.

Director M. Kathleen Behrens reports acquisition of Sarepta Therapeutics stock and stock options.

Director Kathryn Boor reports acquisition of stock options and restricted stock units (RSUs) in Sarepta Therapeutics.

Chief Financial Officer of Sarepta Therapeutics, Ian Michael Estepan, reports acquisition and disposal of company stock and stock options.

Director Richard Barry reports acquisition of Sarepta Therapeutics stock and stock options, along with a disposition of shares held in trust.

EVP and General Counsel of Sarepta Therapeutics, Ryan Brown, reports acquisition and disposal of company stock and stock options.

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports acquisition and disposal of company stock and stock options.